RxDoctor Payments Data

Kavitha Sivaraman, MD

Ophthalmology · Blue Ash, OHNPI 1992016976

Payments from drug & device makers

$7,711in general payments, 2019–2025

Across 52 payments — averaging $148.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Haag-streit USA, Inc.$3K
  • Alcon$1K
  • Glaukos Corporation$1K
  • W. L. Gore & Associates, Inc.$500
  • Johnson & Johnson Surgical Vision, Inc.$407
  • Ocular Therapeutix, Inc.$250
  • plus $811 from 10 others

What the payments were for

  • Consulting fees$4,80062%
  • Travel & lodging$76010%
  • Food & beverage$2,15228%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,711 in reported general payments places this provider in the 85th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$238,665
Medicare patients
464
Services billed
1,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine44$52,063
Prednisolone Acetate593$18,520
Loteprednol Etabonate121$17,548
Lotemax SmLoteprednol Etabonate33$8,623
Ketorolac Tromethamine210$8,412
ValacyclovirValacyclovir Hcl149$5,514
ProlensaBromfenac Sodium13$4,151
Fluorometholone60$4,019
Difluprednate16$2,500
Ofloxacin119$1,704
Acyclovir15$1,569
MoxifloxacinMoxifloxacin Hcl38$1,515
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim172$1,176
Vancomycin Hcl22$672
ErythromycinErythromycin Base25$263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$71$52,06344 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm, Prolensa$20$30,322167 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Blue Ash

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →